2023年7月17日Eli Lilly公布了抗β淀粉样蛋白(Aβ)单克隆抗体Donanemab的3期临床试验TRAILBLAZER-ALZ 2试验结果。试验显示 Donanemab能够有效改善Aβ斑块检测阳性阿尔茨海默症早期症状患者的认…
发布时间:2023-07-17浏览数:732
Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium t…
发布时间:2023-07-17浏览数:544
在2023年7月15日出版的《British journal of clinical pharmacology》上,Corcoran的研发团队发表了KCL-286的健康人群1期临床试验结果,初步验证KCL-286的耐受性良好,主要的不反应为皮肤干燥、皮…
发布时间:2023-07-15浏览数:507
In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76…
发布时间:2021-05-06浏览数:458
Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.
发布时间:2021-02-14浏览数:514
These studies have profound implications for the development of therapeutic Aβ antibodies for Alzheimer's disease.
发布时间:2012-01-06浏览数:513
A beta N3(pE) production and retention may play an early and critical role in senile plaque formation.
发布时间:1995-02-01浏览数:458
横切线®为注册商标
Copyright 2020 横切线®药研苑 备案号:粤ICP备18041379号-3